Skip to main content

Autolus Therapeutics plc 10-Q for FY2026 Q3

Autolus Therapeutics plc (AUTL)

10-Q 2026-11-10 For: 2026-09-30
View Original
Added on November 10, 2026

About this 10-Q

Autolus Therapeutics plc filed this 10-Q on November 10, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Autolus Therapeutics reported AUCATZYL revenue of $41.2 million for the three months ended September 30, 2026, versus $21.1 million, as net loss narrowed to $55.1 million from $79.1 million. Cash and cash equivalents totaled $245.4 million. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$41.24M
up 94.6% from $21.19M a year earlier
Net loss
$55.09M
compared with a net loss of $79.12M a year earlier
Diluted EPS
-$0.21
compared with -$0.30 a year earlier